Atsena Therapeutics has received orphan designation from the European Medicines Agency for its two clinical‑stage gene ...

Johnson & Johnson has announced positive topline results from the phase 3 MonumenTAL‑6 study, which evaluated TECVAYLI and ...

OrbusNeich has enrolled the first patient in its pivotal Japanese clinical trial evaluating its proprietary coronary ...

There are currently no approved pharmacological treatments for cALD in the EU.

Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...

First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...

GSK has secured US FDA approval for Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1‑positive ...

Jasper Therapeutics has completed its all‑stock acquisition of Kira Pharmaceuticals, creating a combined business focused on ...

Lundbeck has received Fast Track designation from the U.S. FDA for Lu AH69593, its lead oral orexin 2 receptor agonist in ...

EpilepsyGTx has partnered with ClearPoint Neuro to enable targeted delivery of its lead gene therapy candidate, EPY201, ahead ...

Nouscom will present new phase 1b/2 data on its off‑the‑shelf cancer immunotherapy NOUS‑209 at the European Society for ...

Ardena has appointed Ariane de Ganck as Chief Scientific Officer, reinforcing its focus on scientific excellence across its ...